Hims & Hers Stock Falls Despite the Latest Wegovy Availability Offer

Hims & Hers (HIMS) announced the availability of Wegovy prescriptions for eligible customers at $549 per month for six months, aiming to expand access to obesity treatments; this follows a recent collaboration with Novo Nordisk to offer Wegovy through the HIMS platform. Despite the potential for revenue growth in the expanding weight management market (estimated to reach $488.42 billion by 2032), HIMS shares declined nearly 8% following the announcement. HIMS reported strong Q1 2025 results with improvements in top and bottom lines, and the stock has surged 165.1% in the past year, significantly outperforming the industry and the S&P 500.

Analysis

Hims & Hers Health, Inc. (HIMS) has announced a new pricing initiative for its Wegovy offering, stating that effective May 22, 2025, new eligible customers will be able to access a six-month supply of the prescription obesity treatment at $549 per month. This strategic move aims to broaden access and affordability within the rapidly expanding weight management market, which Data Bridge Market Research valued at $329.83 billion in 2024 and projects to reach $488.42 billion by 2032, growing at an approximate CAGR of 5%. This new pricing plan builds upon a prior collaboration announced last month with Novo Nordisk, which enabled access to Wegovy through the HIMS platform starting at $599 per month. Despite the company's historical success in boosting top-line revenue through product launches and the significant market opportunity, HIMS shares declined nearly 8% following this recent announcement. This negative short-term market reaction contrasts sharply with the company's strong underlying fundamentals and recent performance metrics: HIMS reported robust improvements in top and bottom lines in its first-quarter 2025 results, delivered a 66.7% earnings surprise in its last reported quarter, possesses an earnings yield of 1.4% (favorable compared to the industry’s negative yield), and its stock has surged 165.1% in the past year, significantly outperforming both its industry (18.3% rise) and the S&P 500 (12.3% gain). The delayed implementation of the new pricing until 2025 and potential concerns over margin impact might be contributing factors to the immediate stock pullback.

Key Decisions for Investors

• Investors should evaluate the recent HIMS share price decline, considering whether the market is adequately factoring in the long-term revenue potential from expanded Wegovy access against the 2025 effective date of the new pricing and potential margin pressures.
• Monitor the company's execution on integrating this new Wegovy pricing strategy, paying close attention to its impact on customer acquisition, subscriber growth, and overall revenue contribution to the Online revenue channel upon implementation in 2025.
• Assess Hims & Hers’ ability to capitalize on the substantial growth projected for the weight management market through its evolving GLP-1 offerings, and how effectively it can translate increased accessibility into sustainable market share and profitability.